Amgen Inc. reported second-quarter 2026 revenue of USD 10.05 billion, surpassing the consensus estimate of USD 9.43 billion by USD 620 million. This represents a 9.5 percent year-over-year increase in quarterly revenue, driven by strong commercial growth from its core portfolio. Despite this positive financial beat, Amgen's stock price fell 1.04 percent to close at USD 403.04 on October 2, 2026, as investors weighed the earnings result against the company's elevated valuation and ongoing demands for pipeline execution. Management provided fiscal 2026 EPS guidance ranging from USD 22.30 to USD 23.50 and projected a non-GAAP operating margin between 45 percent and 46 percent for the year. The company highlighted six key growth drivers that expanded 26 percent year over year, which accounted for 70 percent of second-quarter product sales. This strategic focus underscores Amgen's commitment to balancing continued research investment with strict profitability discipline as it navigates its current market position. Beyond financial metrics, Amgen presented positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease and shared recent progress on IMDELLTRA. The company also detailed its portfolio and pipeline updates at various healthcare conferences held in September 2026. These developments reinforce the investment case by demonstrating tangible advancements in late-stage development alongside robust commercial performance. Amgen's market capitalization stood at USD 217.5 billion as of October 2, 2026, with shares trading 9.8 percent below its 52-week high of USD 447.03. The session volume reached 3,502,867 shares, reflecting active investor engagement despite the price decline. The central narrative for investors remains the interplay between strong numerical execution and the need to deliver on future growth expectations to justify current valuations.